4.8 Article

Deep brain stimulation for refractory obsessive-compulsive disorder (OCD): emerging or established therapy?

期刊

MOLECULAR PSYCHIATRY
卷 26, 期 1, 页码 60-65

出版社

SPRINGERNATURE
DOI: 10.1038/s41380-020-00933-x

关键词

-

资金

  1. Aleva
  2. Elekta
  3. BrainLab
  4. Boston Scientific, USA
  5. Medtronic, USA
  6. NeuroPace
  7. Swedish Research Council
  8. Abbott
  9. Deep Brain Stimulation industry
  10. Medtronic
  11. Boston Scientific
  12. Cyberonics Inc
  13. Research Foundation-Flanders (FWO) [G072909N]
  14. FWO Research Grant [1504614N]
  15. Medtronic Chair for Stereotactic Neurosurgery in Psychiatric Disorders at KU Leuven

向作者/读者索取更多资源

There is still no consensus on whether deep brain stimulation (DBS) for treatment-refractory obsessive-compulsive disorder (OCD) can be considered an established therapy. Some studies suggest that DBS may be effective for some patients, but it is still considered investigational and requires more research evidence.
A consensus has yet to emerge whether deep brain stimulation (DBS) for treatment-refractory obsessive-compulsive disorder (OCD) can be considered an established therapy. In 2014, the World Society for Stereotactic and Functional Neurosurgery (WSSFN) published consensus guidelines stating that a therapy becomes established when at least two blinded randomized controlled clinical trials from two different groups of researchers are published, both reporting an acceptable risk-benefit ratio, at least comparable with other existing therapies. The clinical trials should be on the same brain area for the same psychiatric indication. The authors have now compiled the available evidence to make a clear statement on whether DBS for OCD is established therapy. Two blinded randomized controlled trials have been published, one with level I evidence (Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score improved 37% during stimulation on), the other with level II evidence (25% improvement). A clinical cohort study (N = 70) showed 40% Y-BOCS score improvement during DBS, and a prospective international multi-center study 42% improvement (N = 30). The WSSFN states that electrical stimulation for otherwise treatment refractory OCD using a multipolar electrode implanted in the ventral anterior capsule region (including bed nucleus of stria terminalis and nucleus accumbens) remains investigational. It represents an emerging, but not yet established therapy. A multidisciplinary team involving psychiatrists and neurosurgeons is a prerequisite for such therapy, and the future of surgical treatment of psychiatric patients remains in the realm of the psychiatrist.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据